IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US

Trial Identifier: D5980C00034
Sponsor: AstraZeneca
Collaborator:
IQVIA
Premier Inc
NCTID:: NCT05970263
Start Date: January 2024
Primary Completion Date: December 2025
Study Completion Date: December 2025
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
US, AR Batesville, AR, US, 72501
US, AZ Tucson, AZ, US, 85719
US, DC Washington, DC, US, 20037
US, DE Lewes, DE, US, 19958
US, FL Tampa, FL, US, 33607
US, HI Honolulu, HI, US, 96813
US, IL Chicago, IL, US, 60606
US, IL Peoria, IL, US, 61637
US, KS Wichita, KS, US, 67214
US, MA Springfield, MA, US, 01199
US, MD Salisbury, MD, US, 21801
US, MI Detroit, MI, US, 48202
US, MI Mount Clemens, MI, US, 48043
US, MN Saint Paul, MN, US, 55101
US, NC Statesville, NC, US, 28677
US, NC Winston-Salem, NC, US, 27157
US, NJ Mullica Hill, NJ, US, 08062
US, North Carolina Greenville, North Carolina, US, 27834
US, NY Binghamton, NY, US, 13905
US, NY Bronx, NY, US, 10467
US, NY New Hyde Park, NY, US, 11042
US, NY Watertown, NY, US, 13601
US, OH Cleveland, OH, US, 44106
US, OK Tulsa, OK, US, 74107
US, PA Bethlehem, PA, US, 18015
US, SC Anderson, SC, US, 29621
US, SC Columbia, SC, US, 29203
US, SD Sioux Falls, SD, US, 57105
US, TN Nashville, TN, US, 37205
US, TX Odessa, TX, US, 79761